Patents Examined by Jeffrey H Murray
  • Patent number: 11504350
    Abstract: Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 22, 2022
    Assignee: DAY THREE LABS MANUFACTURING INC.
    Inventors: William Z. Levine, Shimon Lecht, Olga Gabay
  • Patent number: 11498917
    Abstract: The invention relates to a process for the preparation of Lifitegrast of formula (I), which comprises: a) condensation of the compound of formula (II) with the compound of formula (III) to give the compound of formula (IV) wherein R1, R2 and R3 are independently selected from straight or branched C1-C6 alkyl groups; b) chlorination of compound (IV) in the presence of a chlorinating agent (IV), (V), c) condensation of compound (V) with amino acid (VI) to give compound (I), c) condensation of compound (V) with amino acid (VI) to give compound (I), d) optional purification of the crude Lifitegrast in mixtures of polar aprotic solvents and water.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: November 15, 2022
    Assignee: OLON S.P.A.
    Inventors: Giorgio Bertolini, Lazzaro Feliciani, Davide Longoni, Mara Sada, Matteo Valli
  • Patent number: 11492359
    Abstract: The compounds provided herein are phenoxazines that can be used as far red to near-infrared nerve-sparing fluorescent compounds in medical procedures.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: November 8, 2022
    Assignee: Oregon Health & Science University
    Inventors: Summer L. Gibbs, Lei G. Wang, Connor W. Barth
  • Patent number: 11492357
    Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 8, 2022
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan Bae, Seung Hyun Jung, Young Gil Ahn, Kwee Hyun Suh
  • Patent number: 11485718
    Abstract: Embodiments of the present invention provide for syntheses and uses of mechanism-based nutritional colorants from vitamin C and amino-containing compounds, wherein the amino-containing compounds can be one of natural compounds or synthetic compounds, wherein the amino-containing compounds can be made through environmentally-friendly radical reactions that follow the antioxidant mechanism of action of vitamin C.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 1, 2022
    Assignee: WALKER CANCER RESEARCH INSTITUTE, INC
    Inventor: Eduardo Palomino
  • Patent number: 11479558
    Abstract: Disclosed herein are tetrahydropyranoindole compounds and derivatives thereof, as well as their methods of synthesis and use. The disclosed compounds may be synthesized by methods that utilize a cooperative hydrogen bond donor/Brønsted acid system. The disclosed compounds may be useful for treating a disease, disorder, or a symptom thereof in a subject in need thereof, such as pain, swelling, and joint stiffness. The disclosed compounds also may be useful for treating cell proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 25, 2022
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Karl A. Scheidt, Mark A. Maskeri
  • Patent number: 11466019
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: October 11, 2022
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Patent number: 11466020
    Abstract: Provided are compounds and compositions for prevention and/or elimination of Zika virus infection. Also provided are methods for preventing and treating a subject in need of prevention or treatment of Zika virus.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: October 11, 2022
    Assignees: Cornell University, The University of North Carolina at Chapel Hill
    Inventors: Shuibing Chen, Ting Zhou, Lei Tan, Qisheng Zhang
  • Patent number: 11458124
    Abstract: A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: October 4, 2022
    Assignee: UCBBiopharma Srl
    Inventors: Gareth Neil Brace, Daniel Christopher Brookings, Gregory Foulkes, Fabien Claude Lecomte
  • Patent number: 11459306
    Abstract: In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and ?, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: October 4, 2022
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Shi-Xian Deng, Xiaoming Xu, Thomas Diacovo
  • Patent number: 11452724
    Abstract: Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: September 27, 2022
    Assignee: The Regents of the University of Michigan
    Inventors: Eva L. Feldman, Ben Murdock, Stephen Goutman, Stacey Jacoby
  • Patent number: 11447492
    Abstract: Disclosed are quinazoline compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds which are useful in treating diseases associated ErbBs. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: September 20, 2022
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Zhengtao Li, Wei Zhong, Jiabing Wang, Qingbei Zeng, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Patent number: 11440909
    Abstract: 10H-phenothiazine derivatives capable of inhibiting ferroptosis has structural formula (I). The derivatives, pharmaceutically acceptable salts thereof, crystal forms thereof, or solvates thereof exhibit inhibitory effect on ferroptosis, and therapeutic effect on a rat model of focal cerebral ischemia and thus can be used as a main active ingredient in the preparation of ferroptosis inhibitors. The compounds and the inhibitors prepared by the compounds have good medicinal potential and are expected to be used as drug candidates for the treatment of stroke.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: September 13, 2022
    Assignee: CHENGDU HENGHAO INVESTMENT CO. LIMITED
    Inventors: Shengyong Yang, Linli Li
  • Patent number: 11426397
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 30, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • Patent number: 11420970
    Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 23, 2022
    Assignee: NOVARTIS AG
    Inventors: Haibing Deng, Jinbiao Liu, Counde Oyang, Ce Wang, Qitao Xiao, Guoliang Xun, Haiqiang Zeng
  • Patent number: 11414429
    Abstract: Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 16, 2022
    Assignees: RIKEN, JAPANESE FOUNDATION FOR CANCER RESEARCH, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Minoru Yoshida, Hiroyuki Seimiya, Masayuki Okue, Yoko Yashiroda, Fumiyuki Shirai, Takeshi Tsumura, Yuko Kano, Kenichi Washizuka, Nobuko Yoshimoto, Yasuko Kouda, Takehiro Fukami, Tsubasa Chikada, Takashi Watanabe
  • Patent number: 11401269
    Abstract: Disclosed are new intermediates for the synthesis of Linagliptin and of its salts and a process for its preparation involving said intermediates.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: August 2, 2022
    Assignee: CAMBREX PROFARMACO MILANO S.R.L.
    Inventors: Cristina Ciancimino, Michele Tragni, Daniele Vigo, Oreste Piccolo
  • Patent number: 11400096
    Abstract: Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purnergic receptor antagonist and/or adenosine receptor antagonists. The P2 purnergic receptor antagonist being chemical analogs of adenosine receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine. The adenosine receptor antagonists being chemical analogs of the non-hydrolysable ATP analog adenosine 5?[?-thio]triphosphate (ATP?S). Certain embodiments are directed to the use of the chemical analogs to modulate IL-17 activity.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: August 2, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jean X. Jiang
  • Patent number: 11382915
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I).
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas J. Schall, Rajinder Singh
  • Patent number: 11384084
    Abstract: A compound of the Formula I and optionally a pharmaceutically acceptable salt thereof is provided: Formula I, wherein, R is one selected from the group consisting of H and CH3; n is an integer 4 when X is —CH2— and Ar is 1,4-phenyl, or n is an integer ranging from 1 to 4 when X is —CH2— and Ar is either 2?-fluoro-1,4-phenyl or 2,5-thienyl, or n is an integer ranging from 1 to 4 when X is one selected from the group consisting of O, S, —NH—, —NHCHO—, —NHCOCH3—, and —NHCOCF3— and Ar is one selected from the group consisting of (a) 1,4-phenyl, (b) 2?-fluoro-1,4-phenyl, and (c) 2,5-thienyl, or n is an integer 3 when X is —CH2—, R is CH3 and Ar is 1,4-phenyl.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: July 12, 2022
    Assignees: DUQUESNE UNIVERSITY OF THE HOLY SPIRIT, WAYNE STATE UNIVERSITY
    Inventors: Aleem Gangjee, Larry H. Matherly